IFP Advisors’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Hold |
0
| – | – | – | 4306 |
|
|
2019
Q1 | $1K | Sell |
83
-42
| -34% | -$457 | ﹤0.01% | 2249 |
|
|
2018
Q4 | $1K | Buy |
+125
| New | +$2.07K | ﹤0.01% | 3368 |
|
|
2018
Q3 | – | Sell |
-125
| Closed | -$10K | – | 3988 |
|
|
2018
Q2 | $10K | Hold |
125
| – | – | ﹤0.01% | 2902 |
|
|
2018
Q1 | $16K | Hold |
125
| – | – | ﹤0.01% | 2533 |
|
|
2017
Q4 | $16K | Hold |
125
| – | – | ﹤0.01% | 2569 |
|
|
2017
Q3 | $19K | Hold |
125
| – | – | ﹤0.01% | 2629 |
|
|
2017
Q2 | $15K | Buy |
125
+42
| +51% | +$7.01K | ﹤0.01% | 2760 |
|
|
2017
Q1 | $16K | Hold |
83
| – | – | ﹤0.01% | 2650 |
|
|
2016
Q4 | $22K | Hold |
83
| – | – | ﹤0.01% | 2389 |
|
|
2016
Q3 | $33K | Hold |
83
| – | – | ﹤0.01% | 2080 |
|
|
2016
Q2 | $29K | Buy |
83
+76
| +1,086% | +$54.4K | ﹤0.01% | 2108 |
|
|
2016
Q1 | $1K | Sell |
7
-82
| -92% | -$65.2K | ﹤0.01% | 2236 |
|
|
2015
Q4 | $93K | Buy |
+89
| New | +$89.2K | 0.01% | 1224 |
|
IFP Advisors's RGLS Position: Q2 2025 in Review
IFP Advisors held its Regulus Therapeutics (RGLS) position steady in Q2 2025 at 0 shares worth $760. The position accounts for ﹤0.01% of the portfolio, ranked #4306.
IFP Advisors first reported a position in RGLS in Q4 2015 and has held it in 13 quarters since. The position peaked at $93K in Q4 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- IFP Advisors held 0 shares of Regulus Therapeutics worth $760 as of Q2 2025.
- IFP Advisors left its Regulus Therapeutics share count unchanged in Q2 2025.
- Regulus Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2025, its #4306 holding.
- IFP Advisors first reported a position in Regulus Therapeutics in Q4 2015 and has held it in 13 quarters since.
- IFP Advisors's Regulus Therapeutics position peaked at $93K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.